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In the common practice of respiratory allergy, the confirmation by IgE tests of the relationship between the
occurrence and duration of symptoms and the exposure to specific inhalant allergens allows an aetiological
diagnosis. However, to see patients with suggestive history but negative IgE tests is not rare, and this generally
leads to a diagnosis of nonallergic rhinitis or asthma. In many cases, such diagnosis is wrong, because the patient
may be revealed as allergic by using additional testing. This is true for local allergic rhinitis, characterized by an
exclusive IgE production in the nasal mucosa, that may be correctly diagnosed by performing a nasal IgE
measurement or a nasal provocation test with the suspected allergen (s). Another misleading issue is the role of T
cell-mediated, delayed hypersensitivity in the pathophysiology of rhinitis and asthma. Recent studies showed that in
patients with rhinitis or asthma and negative IgE tests, especially when there is a positive history for current or past
atopic dermatitis, the clinical symptoms are actually driven by such mechanism, that may be detected by
performing an atopy patch test (APT). The allergen source most frequently responsible for this kind of allergy is the
house dust mite, but other allergens may also be involved. Thus, before delivering a diagnosis of nonallergic rhinitis
or asthma in patients with negative result to common allergy testing, further tests are needed. To miss the
diagnosis of allergy has obvious consequences in terms of management, including allergen avoidance, patient’s
education, and specific immunotherapy.
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patch testIntroduction
The diagnosis of allergy can be easy, as in the case of a
patient with symptoms of rhinoconjunctivitis in the
months of May and June and positive results to skin
prick tests (SPT) with grass pollen extracts. However,
two main issues make such an optimal combination rela-
tively rare. The first is the natural history of respiratory
allergy, which shows how a first sensitization, often oc-
curring in childhood [1], is commonly followed by sub-
sequent sensitizations to other allergens which define
the polysensitization profile of the average adult patient
[2-4]. To further confound this issue, sensitizations, as
assessed by SPT or in vitro tests, may or may not be
associated to clinical allergy. The simple sensitization
not accompanied by clinical symptoms is defined as* Correspondence: canonica@unige.it
3Allergy and Respiratory Diseases, DIMI, Department of Internal Medicine,
University of Genoa, Largo R. Benzi, Genoa, Italy
Full list of author information is available at the end of the article
© 2013 Incorvaia et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orasymptomatic sensitization [5], but to distinguish the
kind of sensitization in a patient with prolonged dur-
ation of symptoms and multiple positivities to allergy tests
may reveal difficult. The modern approach of the compo-
nent resolved diagnosis, based on testing the purified single
allergen molecules, and requiring the knowledge of their
characteristics as primary genuine sensitizers or simply
cross-reacting components with no clinical significance,
can remarkably help in identifying the true causative aller-
gens [6,7].
The second issue stands on the fact that the common
allergy tests are unable to detect all cases of allergy for
two main reasons: (i) IgE antibodies may be present
exclusively in the mucosal tissue, as occur in local
production of IgE [8], or (ii) the allergic symptoms
are sustained by non-IgE mediated mechanisms. To
miss testing such possibility means to erroneously
classify the patient as nonallergic and consequently
to manage improperly his/her disease.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The first recognitions that IgE may be present exclu-
sively in the nasal mucosa date back to the 1970s [9,10]
and this phenomenon was occasionally reconsidered
[11-14]. In 2003 the term “entopy” was proposed to dif-
ferentiate local IgE production from atopy [13] but the
recent definition by Rondon et al. as local allergic rhinitis
(LAR) seems more convincing [15]. The same authors eval-
uated the prevalence of LAR by a survey on 3860 patients
attending their allergy service in one year, 452 of whom
were selected for rhinitis [16]. An overall number of 428
patients completed the study; 24 were excluded because of
nasal hyperreactivity. LAR was diagnosed in 25.7%, allergic
rhinitis (AR) in 63.1%, and nonallergic rhinitis (NAR) in
11.2%. LAR was diagnosed on the basis of negative SPT
and serum sIgE and positive nasal provocation test (NPT).
In more than one third of LAR patients the onset of rhinitis
was in childhood. The house dust mite (HDM) was the
main sensitizing aeroallergen both in LAR and AR (60%
and 54%, respectively). This finding highlights that LAR is
not rare among patients with rhinitis, therefore to overlook
its search would lead to the non-diagnosis of allergy in a
substantial number of patients undergoing allergologic
evaluation. One method to diagnose LAR is, as proposed
by Rondon, the NPT, but a technique detecting IgE in nasal
mucosa, introduced by Marcucci and Sensi [12] is also
available. With such nasal IgE test, the allergen coupled cel-
lulose derivative is placed in a two-hole applicator strip cov-
ered with a permeable membrane (to avoid the adhesion of
nasal mucus on the substrate) and positioned in the above-
posterior tract of the internal ostium for 10 minutes. The
results are subsequently read according to a colorimetric
reaction and expressed in a scale from 0 (negative) to 4
(highly positive), according to a calibration curve. A recent
study compared the results of NPT and nasal IgE test in 55
children with rhinitis in the periods when Alternaria spores
are present in the air. A concomitant positivity of NPT and
nasal IgE test to Alternaria was observed in about 70% of
patients, while positivity of SPT and NPT was observed
in 27% of patients, this difference being highly sig-
nificant (p < 0.0001). This suggests that sensitisation
to Alternaria is frequently expressed by exclusive produc-
tion of specific IgE in the nasal mucosa [17]. Of note, a cli-
nically relevant polysensitization to aeroallergens may
occur also in patients with LAR and may be detected by
multiple NPT [18].
The pathophysiology of LAR is not fully elucidated, how-
ever a number of possible mechanisms underlying the local
production of IgE were reported. Among them, it was
found that nasal B cells express epsilon-germline gene tran-
scripts and mRNA for the epsilon heavy chain of IgE [19].
In patients with negative result to IgE tests a Th2 inflamma-
tory pattern, with increased number of IgE + B cells, mast
cells and eosinophils, was detected by in situ hybridization[20]. A nasal Th2 IgE-mediated inflammation was specific-
ally confirmed in patients with LAR, in whom cytometric
evaluation in nasal lavage showed a leukocyte-lymphocyte
phenotype with increased number of mast cells, basophils,
eosinophils, CD3+ T cells and CD4+ T cells during natural
exposure to the causative allergen (grass pollen) compar-
able to that of patients with AR [21]; in the same study, the
NPT with grass pollen elicited an immediate response (as-
sociated to release of tryptase) and a late response, as oc-
curs in AR [21]. This pattern was confirmed also in
patients with mite-induced perennial LAR [22]; in both
studies, the rapid and persistent rise of specific IgE from
the baseline following NPT supports the local origin
of the IgE production. What remains to be determined are
the factors differentiating the systemic and local IgE synthe-
sis occurring in the common patient with AR from the ex-
clusive local synthesis occurring in the patient with LAR.
Of note, it was recently reported that in patients with posi-
tive IgE tests but with no clinical symptoms, i.e. the patient
with asymptomatic atopy, there are no local IgE in the nasal
mucosa, and it seems conceivable that this should account
for being asymptomatic. In fact, patients with local but not
systemic IgE, that is, with negative results to IgE tests, have
clinical symptoms, while patients with systemic but not
local IgE are asymptomatic [23].
Testing for a cell-mediated mechanism
Recent research has provided evidence that T-cell medi-
ated reactions to inhalant allergens may sustain respira-
tory symptoms in patients with negative results to SPT
and in vitro IgE tests. The major cause of this kind of re-
action is the HDM, particularly Dermatophagoides
pteronyssinus and Dermatophagoides farinae (belonging
to the family Pyroglyphidae) which produce a wide array
of allergens occurring in mite bodies and faeces. Cur-
rently, there are 22 defined mite allergens, some of them
acting as major allergens based on the recognition by
IgE from more than 50% of mite allergic patients. Most
of these allergens are proteolytic enzymes, as known for
Der p 1 and Der p 2 from D. Pteronyssinus and Der f 1
and Der f 2 from D. farinae [24]. The proteolytic activity
makes Dermatophagoides particularly efficient in sensi-
tizing through the skin. In particular, subjects (and espe-
cially children) with atopic dermatitis (AD) have a
baseline-impaired barrier function that allows proteins
to enter into the viable epidermis [25] and to work as
enhancers of the barrier impairment and triggers of a
IgE response. In the epidermal barrier dysfunction
occurring in AD a pivotal role is played by filaggrin [26].
Filaggrin, which derives from the highly phosphorylated
polypeptide profilaggrin, the main constituent of the
keratohyalin substance in the granular layer, is a structural
protein associated to filaments which are bound to keratin
fibres in epidermal cells. Recent studies found that loss-of
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larly the R501X and 2282de14 mutation, are associated
with the development of AD [27,28]. In this condition, the
airborne proteins produced by HDM, such as cysteine and
serine proteases, have direct proteolytic activity on the skin
that contribute to barrier impairment and delayed barrier
recovery in patients with AD [29], by disrupting epithelial
tight junctions, by inducing degranulation of eosinophils,
and by activating keratinocytes, that leads to increased
production of interleukin (IL)-6, IL-8, and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [30,31].
The altered barrier function facilitates the interaction be-
tween allergens and the local immune cells to initiate the
type-I-immediate and type-IV-delayed hypersensitivity reac-
tions common among patients with AD [32]. These mecha-
nisms account for the major role currently recognized to
HDM in AD [33]. However, in AD the reactivity to HDM
allergens is more often cell-mediated than IgE-mediated,
and this limits the diagnostic role of SPT and in vitro IgE
tests. Instead, the atopy patch test (APT), introduced in
1989 by Ring et al. as a tool to investigate the role of
aeroallergens in AD [34], properly assesses the type-IV
delayed hypersensitivity, based on notable evidence
supporting its capacity to reproduce the pathophysiologic
events of AD. In biopsy-based studies, a Th2 cytokine pat-
tern was found 24 hours after APT, but a shift to a Th1 pat-
tern, as occurs in chronic AD skin lesions, was noted after
48 hours [35,36]. A more frequent positivity to APT was
reported in patients with allergen-specific lymphocyte
proliferation and expression of activation markers on per-
ipheral blood T-cells following in vitro stimulation with
HDM, but also with cat or grass pollen allergens, than in
patients without lymphocyte proliferation [37]. Application
of the APT to skin of subjects with AD was followed by an
influx of inflammatory dendritic epidermal cells [38]. By
immunohistochemical analysis, the presence of IgE on
Langerhans cells was demonstrated in positive APT reac-
tions to HDM in patients with mite-associated AD [39].
Clinically, patients with a diagnosis of intrinsic AD because
of negative IgE tests actually had a positive APT for dust
mites [40]. This aspect is of particular interest, because AD
patients with negative SPT and IgE measurement in serum
should be classified as nonatopic unless APT is performed.
In a European multicenter study, which included 314
patients with AD, the frequency of positive APT reactions
to HDM was 39%, and a positive APT without SPT or sIgE
for the respective allergen was seen in 17% of the patients
[41]. New significant observations increased the value of
the APT by showing that in children with respiratory symp-
toms an exclusive positivity to APT with HDM can be
detected [42]. This is also true in children with mite-
induced asthma and rhinitis with positive SPT and specific
IgE in serum, in 25% of cases a positive APT to HDM
is found, indicating that delayed hypersensitivity wasconcurrent to immediate hypersensitivity [43]. Further
studies investigated the possible factors underlying the posi-
tive result of APT in subjects with respiratory symptoms.
In a study conducted on 297 children it was demonstrated
that in subjects with asthma or rhinitis a positive APT to
HDM was strongly associated with the presence of current
or past AD, while most subjects with respiratory disease
but a negative history for AD had a positive SPT [44].
Multivariate analysis showed a highly increased likelihood
of a positive APT result in patients with AD (odds ratio
17.4), in patients with AD and respiratory disease (odds ra-
tio 21.9), and in patients with past AD and respiratory dis-
ease (odds ratio 22.8). These observations were confirmed
in a study on a large population of 465 children, divided
into 4 groups: group A, current AD (40 patients); group B,
current AD with respiratory symptoms (156 patients);
group C, past AD with respiratory symptoms (203 pa-
tients); and the control group, respiratory symptoms with
no history of AD (66 patients). The APT was significantly
more frequently positive in groups with current AD
(groups A and B) or past AD (group C) than in the control
group, while SPT and specific IgE in serum were signifi-
cantly more frequently positive in the control group [45].
Such significant differences in response to APT in patients
with dissimilar clinical expressions suggest that distinctive
immunologic mechanisms underlie the different manifesta-
tions of hypersensitivity to dust mites. One may conceive
that in subjects with a negative history for AD sensitization
to mites occurs by respiratory route and leads to the devel-
opment of a Th2 pattern of response with ongoing produc-
tion of specific IgE and consequent positive SPT and
in vitro IgE tests. By contrast, if the mite allergens enter
through the skin, as can occur during exposure to common
indoor concentrations of the major allergen Der p 1 [46],
such entering being facilitated by its proteolytic activity and
in the presence of a skin barrier dysfunction, a different
chain of events is likely to take place, which is revealed by
positive APT and negative SPT and in vitro IgE tests. This
knowledge should change the attitude of allergy specialists
to using the ATP, especially when patients with rhinitis or
asthma, positive history for past AD, and negative IgE test
are to be evaluated [47]. However, thus far there are no
studies demonstrating that in patients with negative IgE
tests there is an isolated late response to allergen challenge.
Further studies should assess the diagnostic value of the
APT by comparing its result with the effect of allergen ex-
posure (better if proved by a nasal challenge). A correlation
between the results of the two tests should confirm the reli-
ability of the APT.
How to manage patients with suspected allergy and
negative IgE tests
It is common knowledge that not all patients with rhinitis
or asthma are allergic. Concerning the latter, “intrinsic”
Figure 1 Diagnostic flow-chart to detect forms of allergy different from the common IgE-mediated hypersensitivity.
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[48], while nonallergic rhinitis seems to affect approxi-
mately 8% of the general population in the USA [49], this
figure being close to the 11% in Spain as reported by
Rondon et al. in the study cited above [16]. In both diseases,
it can be argued that if the allergologic evaluation is not
limited to SPTand in vitro IgE tests, the number of patients
diagnosed as nonallergic could be substantially reduced. To
diagnose LAR, which currently is a well defined clinical en-
tity, a NPT or a measurement of nasal IgE are required. For
the latter, a recent study showed that using molecular diag-
nosis, with identification of IgE to single allergen compo-
nents, may strengthen the significance of the findings [50].
In addition, in recent years the possibility that rhinitis or
asthma are sustained by a T-cell mediated mechanism has
gained increasing recognition. The picture suggesting such
mechanism is characterized by a positive history for past or
current AD and negative IgE tests. The test required to es-
tablish that a T-cell mediated, delayed hypersensitivity, is
driving the clinical symptoms of the patient, is the APT.
The allergen source most frequently responsible for T-cell
mediated rhinitis or asthma is the HDM, but other aller-
gens may also be involved [47]. Thus, in patients with posi-
tive history and negative skin tests or in vitro IgE tests,
testing for LAR or T-cell mediated allergy should be
added as third level examination, using a flow-chart as
suggested in Figure 1. To reach an accurate diagnosis of
allergy by using the correct tests in a patient otherwiseclassified as nonallergic has obvious consequences in
terms of management, including allergen avoidance, pa-
tient’s education, and specific immunotherapy. For ex-
ample, a preliminary study on 20 patients with grass
pollen-induced seasonal LAR, 10 treated with subcutane-
ous immunotherapy with a grass-pollen extract and 10
with symptomatic drugs, reported that immunotherapy
was effective, as assessed by their symptoms score during
the pollen season, and well tolerated; in addition, im-
munologic effects on IgG and IgE antibodies, comparable
to the pattern of response observed in patients with AR,
were found [51]. A confirmation of such outcome from
controlled trials including an adequate number of patients
should make more convincing this issue.
The feasibility of immunotherapy deserves to be inves-
tigated also in patients with rhinitis or asthma and evi-
dence of a T-cell mediated hypersensitivity as indicated
by positive APT.Competing interests
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